GU Cancers 2019 | Savolitinib plus durvalumab show promise in papillary renal cancer: CALYPSO results

Thomas Powles

Papillary renal cancer accounts for approximately 10% of renal cancer, and due to the smaller patient population it has not been investigated as vigorously as clear cell renal cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, reports that the Phase II CALYPSO trial (NCT02819596) investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer, has demonstrated encouraging efficacy data and has the potential to breach a new path to treating kidney cancer. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video